First Week of February 2026 Options Trading For Harrow (HROW)

Harrow Inc. (HROW) is highlighted for two options strategies around the current share price of $47.27. A sell-to-open $46 put (bid $3.80) would set an effective purchase cost basis of $42.20 and is ~3% out-of-the-money with a 61% probability of expiring worthless, implying an 8.26% yield on cash (50.25% annualized) if it does. On the call side, selling a $55 covered call (bid $1.80) against shares bought at $47.27 would cap upside at $55 but generate a 20.16% total return if assigned at the February 2026 expiry and has a 66% chance of expiring worthless, representing a 3.81% immediate boost (23.16% annualized). Implied volatility is 78% for the put and 65% for the call versus a 12‑month trailing volatility of 61% (249 trading days).

Analysis

Market structure: Option sellers and income-oriented holders are the immediate beneficiaries — selling the HROW $46 put collects $3.80 today (net basis $42.20) and selling the $55 covered call funds ~20% capped upside to Feb 2026. Elevated put IV (78%) versus call IV (65%) and TTM vol (61%) signals asymmetric downside risk pricing and a willingness of buyers to pay for downside protection; liquidity and skew suggest limited market-making stress but higher risk premia for tail exposure. Cross-asset effects are minimal systemically, but quarrying premium in small-cap options can increase repo/financing sensitivity and push local funding volatility into small-cap credit spreads and short-dated single-name CDS if a shock occurs.

Risk assessment: Tail risks are idiosyncratic — a company-specific operational/regulatory shock could move HROW >30% and blow past the $46 put seller’s cash reserve; assignment risk and margin expansion are non-linear. In the next days–weeks, theta decay favors sellers; in months (to Feb 2026) IV mean reversion could compress premium by 10–30 pts; over years fundamental performance will dominate. Hidden dependencies include borrow costs for covered-call hedgers, corporate actions (dividends/secondary) that change early exercise economics, and concentrated position risk if assigned. Key catalysts: quarterly results, FDA/regulatory announcements (if applicable), or a deal/tender within 60–180 days.

Trade implications: Direct: implement cash-secured puts (HROW $46) sized 0.5–2% NAV targeting $42.20 effective cost, only if willing to own shares at that basis; prefer limit credit ≥$3.80. Safer alternative: sell $46/$40 put spread to cap max loss (width $6 less premium) if downside protection required. Covered-call: buy-to-open HROW and sell $55 Feb 2026 calls to harvest 3.8% premium now with 16% upside cap — allocate 0.5–1% NAV. If directional bearish on small caps, short small-cap beta or buy put protection rather than naked short HROW.

Contrarian angles: Consensus underprices the skew — put IV > call IV by ~13 pts implies outsized tail demand, which could overstate fundamental downside if next 60-day catalysts are benign; IV could revert lower, benefiting sellers. Conversely, reaction may be underdone if a negative event occurs: naked put sellers can be forced into concentrated long positions at materially worse prices. Historical parallels show small-cap option-rich setups around earnings often mean-revert within 30–90 days; monitor assignment triggers (10–15% moves) to avoid forced accumulation.

Key Decisions for Investors

• Establish a cash-secured sell-to-open on HROW $46 put (Feb 2026 or nearest) sized 0.5–2.0% of NAV with a limit credit ≥$3.80 (net basis $42.20). Close or buy-to-close if HROW trades below $40 (≈15% haircut from $47.27) or IV rises >20 pts to limit tail exposure.
• Buy HROW shares (size 0.5–1.0% NAV) and sell-to-open the $55 Feb 2026 covered call for premium ≈$1.80 to lock a 20.2% capped total return; roll or unwind if stock >$55 or if IV compresses >10 pts within 90 days.
• Prefer defined-risk put credit spread instead of naked put: sell HROW $46 / buy $40 (same expiry) to limit max loss to $6 minus net premium; target max portfolio hit of ≤2% NAV and enter when net credit ≥$2.00.
• If shorting volatility is undesirable, take a pair trade: long HROW via buy-write (buy + sell $55 call) and short equivalent small-cap ETF exposure (e.g., 50–100 bps notional in RSP or IWM) to neutralize market beta while harvesting premium; rebalance monthly.
• Monitor three triggers over next 60 days and act: (1) IV differential put-call >+20 pts (close sells), (2) HROW move >±12% intraday (review assignment/take-profit), (3) company-specific filings/earnings/regs — exit premium trades 5 trading days before such events to avoid gap risk.